Results 131 to 140 of about 820 (140)

Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline

Haemophilia, 2020
P Vincent Jenkins, Annette Bowyer, Elaine Gray   +2 more
exaly  

The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia

Haemophilia, 2020
Laurie J Brown, Hai Anh La, Jinjing Li
exaly  

Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies

Blood Advances, 2019
Angela C Weyand, Veronica H Flood, Jordan A Shavit   +2 more
exaly  

Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

Haemophilia, 2020
Christine Guelcher, Janice Kuhn, Michael F Guerrera   +2 more
exaly  

Emicizumab

2018
Tiede, Andreas, Wörmann, Bernhard, Klamroth, Robert, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +4 more
openaire   +1 more source

<p>Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A</p>

Drug Design, Development and Therapy, 2020
Sandra Le Quellec
exaly  

Emicizumab for non-severe haemophilia A

The Lancet Haematology, 2023
openaire   +2 more sources

Emicizumab for infants and children with haemophilia A

British Journal of Haematology, 2020
openaire   +2 more sources

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort

Pediatric Blood and Cancer, 2019
Assaf Arie Barg, Einat Avishai, Ivan Budnik   +2 more
exaly  

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Journal of Thrombosis and Haemostasis, 2018
Keiji Nogami
exaly